ALK and non-small cell lung carcinoma: Then the Food and Drug Administration (FDA) approved crizotinib as the first TKI for ALK‐positive patients with advanced NSCLC in 2011, followed by its approval of the National Medical Products Administration (NMPA) in 2013.